Xenon Pharma Files Q1 2025 10-Q
Ticker: XENE · Form: 10-Q · Filed: May 12, 2025 · CIK: 1582313
| Field | Detail |
|---|---|
| Company | Xenon Pharmaceuticals Inc. (XENE) |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals, equity-incentive-plan
Related Tickers: XENE
TL;DR
Xenon Pharma's Q1 2025 10-Q is in: updates on equity plans and asset deals.
AI Summary
Xenon Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial position and business activities, including details on its equity incentive plans and asset purchase agreements. Specific financial instruments like Guaranteed Investment Certificates and Corporate Debt Securities were noted.
Why It Matters
This filing provides investors with an update on Xenon Pharmaceuticals' financial health and operational activities for the first quarter of 2025, crucial for understanding the company's trajectory.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Xenon faces inherent risks related to drug development, regulatory approvals, and market competition, which are not fully detailed in this summary but are typical for the sector.
Key Numbers
- Q1 2025 — Reporting Period (The period covered by the 10-Q filing.)
- 2025-03-31 — As of Date (The specific date for which financial information is reported.)
Key Players & Entities
- Xenon Pharmaceuticals Inc. (company) — Filer of the 10-Q
- 2025-03-31 (date) — End of the reporting period
- First Order Pharmaceuticals Inc. (company) — Mentioned in relation to an Asset Purchase Agreement
- 2025-01-01 (date) — Start of the reporting period for certain activities
FAQ
What is the primary business of Xenon Pharmaceuticals Inc.?
Xenon Pharmaceuticals Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
What specific equity incentive plan was mentioned for the period?
The 'TwoThousandTwentyFiveInducementEquityIncentivePlanMember' was mentioned, with activity between February 1, 2025, and February 28, 2025.
Was there any mention of asset purchase agreements?
Yes, an 'Asset Purchase Agreement' involving 'First Order Pharmaceuticals Inc.' was noted for the period between January 1, 2025, and March 31, 2025.
What types of financial instruments were referenced in the filing?
The filing references Guaranteed Investment Certificates, Corporate Debt Securities, and Commercial Paper.
What is Xenon Pharmaceuticals' fiscal year end?
Xenon Pharmaceuticals' fiscal year ends on December 31.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Xenon Pharmaceuticals Inc. (XENE).